STROBE Statement

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used	1
		term in the title or the abstract	
		(b) Provide in the abstract an informative and balanced	1
		summary of what was done and what was found	
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the	2
		investigation being reported	
Objectives	3	State specific objectives, including any prespecified	3
		hypotheses	
Methods			
Study design	4	Present key elements of study design early in the paper	3-6
Setting	5	Describe the setting, locations, and relevant dates,	3-5
		including periods of recruitment, exposure, follow-up,	
		and data collection	
Participants	6	(a) Give the eligibility criteria, and the sources and	3
		methods of selection of participants	
Variables	7	Clearly define all outcomes, exposures, predictors,	3-5
		potential confounders, and effect modifiers. Give	
		diagnostic criteria, if applicable	
Data sources/	8*	For each variable of interest, give sources of data and	3-6 and Supplementary
measurement		details of methods of assessment (measurement).	Materials
		Describe comparability of assessment methods if there is	
		more than one group	
Bias	9	Describe any efforts to address potential sources of bias	3-6
Study size	10	Explain how the study size was arrived at	3 and Supplementary
			Figure 2
Quantitative variables	11	Explain how quantitative variables were handled in the	3-6
		analyses. If applicable, describe which groupings were	
		chosen and why	
Statistical methods	12	(a) Describe all statistical methods, including those used	5-6
		to control for confounding	
		(b) Describe any methods used to examine subgroups	5-6
		and interactions	
		(c) Explain how missing data were addressed	5-6
		(d) If applicable, describe analytical methods taking	NA
		account of sampling strategy	
		(e) Describe any sensitivity analyses	NA
Results			
Participants	13*	(a) Report numbers of individuals at each stage of	Supplementary Figures
		study—eg numbers potentially eligible, examined for	1 and 2;
		eligibility, confirmed eligible, included in the study,	Supplementary Table 3
		completing follow-up, and analysed	
		(b) Give reasons for non-participation at each stage	Supplementary Figure
			$\frac{1}{2}$

		(c) Consider use of a flow diagram	Supplementary Figure 2
Descriptive data	14*	(a) Give characteristics of study participants (eg	Table 1 and
		demographic, clinical, social) and information on	Supplementary Table 4
		exposures and potential confounders	
		(b) Indicate number of participants with missing data for	Table 1 and
		each variable of interest	Supplementary Table 3
Outcome data	15*	Report numbers of outcome events or summary measures	7-20
Main results	16	(a) Give unadjusted estimates and, if applicable,	Supplementary
		confounder-adjusted estimates and their precision (eg,	Materials
		95% confidence interval). Make clear which confounders	
		were adjusted for and why they were included	
		(b) Report category boundaries when continuous	7-20
		variables were categorized	
		(c) If relevant, consider translating estimates of relative	NA
		risk into absolute risk for a meaningful time period	
Other analyses	17	Report other analyses done—eg analyses of subgroups	NA
		and interactions, and sensitivity analyses	
Discussion			
Key results	18	Summarise key results with reference to study objectives	21-24
Limitations	19	Discuss limitations of the study, taking into account	24-25
		sources of potential bias or imprecision. Discuss both	
		direction and magnitude of any potential bias	
Interpretation	20	Give a cautious overall interpretation of results	25
		considering objectives, limitations, multiplicity of	
		analyses, results from similar studies, and other relevant	
		evidence	
Generalisability	21	Discuss the generalisability (external validity) of the	24-25
		study results	
Other information			
Funding	22	Give the source of funding and the role of the funders for	25
		the present study and, if applicable, for the original study	
		on which the present article is based	

^{*}Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.